Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,288.60 +11.09 (+0.21%) Dow
38,643.39 -42.93 (-0.11%) Nasdaq
16,835.53 +100.52 (+0.60%) Bitcoin USD
69,689.99 +1,651.35 (+2.43%) CMC Crypto 200
1,508.60 +40.67 (+2.77%)
FGEN Sep 2024 4.500 call
| Previous close | 0.2300 |
| Open | 0.2300 |
| Bid | 0.0000 |
| Ask | 0.7000 |
| Strike | 4.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.2300 - 0.2300 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswireFibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global Healthcare Conference to be held in Miami, Florida on Monday, June 10, 2024, from 10:00-10:35 AM Eastern Time. Company management will also participate in one-on-one meetings with investors during the conference. A live audio webcast of the event will be available to investors and other i
- GlobeNewswire
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patientsFG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugate therapies with a MMAE payloadRecommended Phase 2 dose of FG-3246 was established at 2.1 mg/kg every 3 weeks in combination with enzalutamide given at the standard dose of 160 mg daily SAN FRANCISCO, May 23, 2024 (GLO
Simply Wall St.FibroGen First Quarter 2024 Earnings: Beats Expectations
FibroGen ( NASDAQ:FGEN ) First Quarter 2024 Results Key Financial Results Revenue: US$55.9m (up 55% from 1Q 2023). Net...
